See more : Genus plc (GNS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Guardant Health, Inc. (GH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardant Health, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- ArcticZymes Technologies ASA (AZT.OL) Income Statement Analysis – Financial Results
- Veer Global Infraconstruction (VGIL.BO) Income Statement Analysis – Financial Results
- Metarock Group Limited (MYE.AX) Income Statement Analysis – Financial Results
- CT Vision S.L. (International) Holdings Limited (0994.HK) Income Statement Analysis – Financial Results
- Majorel Group Luxembourg S.A. (MAJ.AS) Income Statement Analysis – Financial Results
Guardant Health, Inc. (GH)
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 563.95M | 449.54M | 373.65M | 286.73M | 214.38M | 90.64M | 49.84M | 25.25M |
| Cost of Revenue | 227.05M | 156.33M | 122.91M | 92.54M | 70.72M | 43.21M | 31.62M | 22.12M |
| Gross Profit | 336.90M | 293.21M | 250.74M | 194.20M | 143.66M | 47.43M | 18.22M | 3.13M |
| Gross Profit Ratio | 59.74% | 65.23% | 67.11% | 67.73% | 67.01% | 52.33% | 36.56% | 12.38% |
| Research & Development | 367.19M | 373.81M | 263.22M | 149.86M | 86.29M | 50.71M | 25.56M | 10.86M |
| General & Administrative | 155.80M | 163.96M | 206.64M | 192.77M | 61.40M | 36.19M | 36.78M | 9.92M |
| Selling & Marketing | 295.23M | 299.83M | 191.88M | 106.51M | 78.34M | 53.47M | 32.50M | 26.19M |
| SG&A | 451.03M | 463.78M | 398.52M | 299.28M | 139.73M | 89.66M | 69.27M | 36.11M |
| Other Expenses | 83.40M | -112.56M | 25.18M | 3.64M | 88.00K | 4.70M | -1.06M | -1.00K |
| Operating Expenses | 901.62M | 837.59M | 661.74M | 449.15M | 226.03M | 140.37M | 94.84M | 46.97M |
| Cost & Expenses | 1.13B | 993.92M | 784.65M | 541.68M | 296.75M | 183.58M | 126.45M | 69.10M |
| Interest Income | 35.37M | 6.07M | 3.93M | 10.17M | 13.74M | 5.27M | 2.23M | 733.00K |
| Interest Expense | 2.58M | 2.58M | 2.58M | 4.77M | 1.18M | 1.25M | 2.70M | 3.02M |
| Depreciation & Amortization | 42.88M | 35.96M | 22.27M | 16.07M | 13.61M | 7.14M | 5.21M | 3.69M |
| EBITDA | -433.31M | -614.91M | -359.62M | -225.07M | -54.93M | -75.84M | -75.31M | -39.42M |
| EBITDA Ratio | -76.83% | -144.79% | -102.21% | -84.10% | -31.97% | -91.54% | -140.91% | -156.13% |
| Operating Income | -564.73M | -544.38M | -411.00M | -254.95M | -82.37M | -92.94M | -76.61M | -43.85M |
| Operating Income Ratio | -100.14% | -121.10% | -110.00% | -88.92% | -38.42% | -102.54% | -153.71% | -173.66% |
| Total Other Income/Expenses | 85.96M | -109.07M | 26.53M | 9.05M | 12.65M | 8.72M | -6.60M | -2.29M |
| Income Before Tax | -478.76M | -653.45M | -384.47M | -245.90M | -69.72M | -84.23M | -83.21M | -46.13M |
| Income Before Tax Ratio | -84.90% | -145.36% | -102.89% | -85.76% | -32.52% | -92.92% | -166.96% | -182.71% |
| Income Tax Expense | 685.00K | 1.14M | 300.00K | 379.00K | -1.87M | 38.00K | 7.00K | 6.00K |
| Net Income | -479.45M | -654.59M | -384.77M | -246.28M | -67.85M | -85.06M | -83.22M | -46.14M |
| Net Income Ratio | -85.02% | -145.61% | -102.98% | -85.89% | -31.65% | -93.85% | -166.97% | -182.74% |
| EPS | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| EPS Diluted | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| Weighted Avg Shares Out | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
| Weighted Avg Shares Out (Dil) | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
US FDA approves Guardant Health's blood-based cancer test
Guardant Health's Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
3 Precision Medicine Stocks Tailoring Treatments
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
The 3 Best Personalized Medicine Stocks to Buy in July 2024
From ‘Sell' to ‘Strong Buy': 3 Dramatic Analyst U-Turns to Watch
Guardant Health (GH) Just Overtook the 20-Day Moving Average
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
Guardant Health Named to TIME100 Most Influential Companies
Source: https://incomestatements.info
Category: Stock Reports